Detomax IV infusion: Each vial contains Dexmedetomidine Hydrochloride USP equivalent to Dexmedetomidine 200 mcg. Each normal saline bottle contains 48 ml 0.9% Sodium Chloride solution.
Dexmeditomidine is a relatively selective alpha2-adrenergic agonist with sedative properties.
Dexmeditomidine is a relatively selective alpha2-adrenergic agonist indicated for:
Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Administer Dexmeditomidine by continuous infusion not to exceed 24 hours.
Sedation of non-intubated patients prior to and/or during surgical and other procedures.
Individualize and titrate Dexmeditomidine dosing to desired clinical effect.
Administer Dexmeditomidine using a controlled infusion device.
Dilute the 200 mcg/2 mL (100 mcg/mL) vial contents in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration.
The 200 mcg/50mL single-use bottles do not require further dilution prior to administration.
For Adult Intensive Care Unit Sedation: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/hour.
For Adult Procedural Sedation: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hour.
Alternative Doses: Recommended for patients over 65 years of age and awake fiberoptic intubation patients.
Continuous monitoring is needed while patient receiving Dexmedetomidine.
Pregnancy Category C
Co-administration of Dexmedetomidine with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
Bradycardia, hypotension and cardiac arrest is observed.
Detomax IV infusion: Each pack contains one vial (2 ml) with carton, 48 ml normal saline in a glass bottle, one infusion set, hanger and one 5 ml disposable syringe.